aibio.space Legal & Regulatory Desk
Securities class actions, derivative suits, patent cases, SEC and DOJ matters, subpoenas and settlements. Law-firm claims are reported as allegations.
Sources: SEC filings and company press releases, with wires, trade press and court dockets used as leads and confirmed against a filing. The desk follows our editorial standards. 146 stories so far.
Latest stories
- Alnylam details Texas patent suit, two Cipla patent cases and a U.S. Attorney subpoena
- Viking and Ligand dispute VK2809 license termination in San Diego court
- Viking's ITC trade secret ruling against Ascletis is on appeal at Federal Circuit
- Court rules for Teva and Apotex in Vanda's HETLIOZ patent suits
- Indivior discloses Suboxone dental injury MDL of about 22,098 plaintiffs; no bellwether before 2028
- European patent court rules Enanta patent invalid in Paxlovid suit against Pfizer
- Skye Bioscience faces nimacimab securities class action and two derivative suits
- Skye Bioscience faces October 2026 retrial of Cunning whistleblower suit
- Amarin settles Hikma patent and antitrust cases over generic Vascepa
- Replimune 10-Q lists two Massachusetts securities class actions and consolidated derivative suits
- Beta Bionics discloses securities class action over iLet statements
- Integra LifeSciences details New Jersey class action and two derivative suits in 10-Q
- CSL faces shareholder class action over FY26 guidance and disclosure
- Medpace discloses plaintiff dropped Ohio securities class action over book-to-bill ratio
- SomaLogic stockholder suit heads to 2027 trial without Standard BioTools; Palamedrix claim settled
- Lifecore reports July hearing on securities class action settlement
- Fifth Circuit vacates class certification in Filana securities class action
- Collegium settles Grünenthal patent suit over Nucynta ER generic for $17,000,000
- Ultragenyx and Baylor settle Dojolvi patent litigation with Navinta, generic entry set for 2033
- Supernus inherits Sage securities class action, derivative suits and SEC subpoena
- Actinium securities class action dismissed with prejudice; plaintiffs file appeal
- Jasper Therapeutics faced Oct 15 hearing on motion to dismiss briquilimab class action
- Liquidia settles all patent and trade secret litigation with United Therapeutics
- Xeris sues Torrent, Rising and others in New Jersey over generic Keveyis patent
- Weird Science demands $10 million to end Delaware Chancery suit and other claims against Lunai
- Lunai Bioworks cites its Delaware suit against Seven Points Capital in Nasdaq trading halt request
- Envoy Medical ends Atlas SPAC redemption suit in Delaware with no payment
- Neogen discloses appeal of dismissed Michigan securities suit and two related cases
- Inovio faces securities class action and five derivative suits over INO-3107 statements
- Tonix gets Paragraph IV patent notice from Dr. Reddy's on generic TONMYA application
- Lantheus discloses three stockholder suits over its Curium merger and 16 demand letters
- Unicycive discloses another securities class action over its OLC application
- Jury awards Nektar $90 million in Lilly contract case; securities class action pending
- Sarepta faces securities class action and five derivative suits over Elevidys disclosures
- AnaptysBio awaits post-trial argument in Delaware suit against GSK and Tesaro
- Aquestive faces securities class action and derivative suit over Anaphylm NDA statements
- Beta Bionics discloses securities class action filed September 4, 2026 over iLet statements
- Cardiff Oncology settles onvansertib license lawsuit with Nerviano Medical Sciences
- Acadia derivative settlement gets preliminary approval as securities class action stays pending
aibio